Researchers at the University of North Carolina have questioned the FDA's need for genetic screening for cancer drugs irinotecan, as it is needless. Irinotecan, also known as Camptosar, is used mainly as a second-line treatment for colorectal cancer. The FDA ha prescribed the screening as they were afraid that many will be vulnerable to harmful side effects of the drug. They were particularly worried about neutropenia, an abnormally low number of white blood cells.
In a paper published in the Aug. 28, 2007 Journal of the National Cancer Institute, UNC researchers analyzed data from nine previous studies of irinotecan. They found that patients who received a medium or high dose of the drug had greater risk of neutropenia if they had two copies of a variation of the gene UGT1A1, known as UGT1A1*28. At lower doses, however, the risk was the same regardless of what UGT1A1 gene the patients had.
"Many institutions saw the FDA's recommendation as a mandate to test all patients before treating them with irinotecan even though many clinicians didn't think it was always necessary given that low doses of the drug weren't causing problems," said Howard McLeod, Pharm.D., senior author of the study and director of the UNC Institute for Pharmacogenomics and Individualized Therapy.
"There are so many treatment options for cancer patients that the more information we have about matching the right therapy to the patient, the better off we all are," Goldberg said. "Studies like this one give oncologists the tools needed to take better care of patients while avoiding tests and expenses that aren't needed."
The authors recommended that the FDA amend the product information for irinotecan to describe the association between irinotecan dose and risk of hematologic toxicity among patients with two UGT1A1*28 genes.